LASA vs WOCKPHARMA: Stock Comparison

LASA SUPERGENERICS vs WOCKHARDTUpdated 4 Sept 26, 4:08 PM ISTNSE & company filings

WOCKHARDT is the larger company by market capitalisation. LASA SUPERGENERICS shows lower leverage, while WOCKHARDT shows a higher ROE, faster revenue growth and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

LASA leads 2; WOCKPHARMA leads 7 of 11

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

LASAWOCKPHARMA

Valuation lens

What price are you paying?

Market CapContext only
₹34 Cr
₹33,908 Cr
P/E RatioSame reading
75.68x
P/B RatioSame reading
6.27x
EPSWOCKPHARMA has the higher reading
₹-0.71
₹6.58
Book ValueContext only
₹9.9
₹325
Dividend YieldSame reading
0%
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
WOCKPHARMA is the larger company
₹33,908 Cr vs ₹34 Cr
EPS
WOCKPHARMA has higher earnings per share
₹6.58 vs ₹-0.71
Revenue Growth (TTM YoY)
WOCKPHARMA has faster revenue growth
26% vs 0%
Qtr Sales Growth
WOCKPHARMA has stronger quarterly sales growth
-39.61% vs -95.12%
Qtr Profit Growth
LASA has stronger quarterly profit growth
89.5% vs 0%
ROE
WOCKPHARMA has a higher ROE
10.28% vs -68.7%
ROCE
WOCKPHARMA has a higher ROCE
10.37% vs -57.92%
Net Margin
WOCKPHARMA has a higher net margin
3.3% vs -135.6%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricLASAWOCKPHARMA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricLASAWOCKPHARMA
Live Price₹6.73₹2,088.7
Day Change-1.32%7.08%
Volume24,57535.58 L
52-Week High₹14.08₹2,422.3
52-Week Low₹5.67₹1,086.7
Distance from 52W High-52.2%-13.77%

Valuation

MetricLASAWOCKPHARMA
Market Cap₹34 Cr₹33,908 Cr
P/E Ratio75.68x
P/B Ratio6.27x
EPS₹-0.71₹6.58
Book Value₹9.9₹325
Dividend Yield0%0%

Growth

MetricLASAWOCKPHARMA
Revenue Growth (TTM YoY)0%26%
EPS Growth (TTM YoY)0%0%
Qtr Sales Growth-95.12%-39.61%
Qtr Profit Growth89.5%0%

Profitability & Leverage

MetricLASAWOCKPHARMA
ROE-68.7%10.28%
ROCE-57.92%10.37%
Net Margin-135.6%3.3%
Operating Margin-136.12%28.35%
Debt to Equity0.2x0.57x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricLASAWOCKPHARMA
Promoter Holding53.65%49.08%
FII Holding0%7.22% 0.13 pp
DII Holding0%9.24% 1.72 pp
Public Holding46.35%34.44% 1.61 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: LASA SUPERGENERICS and WOCKHARDT.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.